SBTX vs. ZYME, CALT, ETHZ, AVTE, NLTX, BIOA, VIRI, WHWK, SPRB, and LITS
Should you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include Zymeworks (ZYME), Calliditas Therapeutics AB (publ) (CALT), Flag Ship Acquisition (ETHZ), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), Spruce Biosciences (SPRB), and Lite Strategy (LITS).
Silverback Therapeutics vs. Its Competitors
Silverback Therapeutics (NASDAQ:SBTX) and Zymeworks (NASDAQ:ZYME) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.
74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by insiders. Comparatively, 1.9% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500.
In the previous week, Silverback Therapeutics had 2 more articles in the media than Zymeworks. MarketBeat recorded 2 mentions for Silverback Therapeutics and 0 mentions for Zymeworks. Silverback Therapeutics' average media sentiment score of 0.58 beat Zymeworks' score of 0.00 indicating that Silverback Therapeutics is being referred to more favorably in the media.
Silverback Therapeutics has a net margin of 0.00% compared to Zymeworks' net margin of -59.96%. Zymeworks' return on equity of -21.59% beat Silverback Therapeutics' return on equity.
Silverback Therapeutics has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Zymeworks beats Silverback Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Silverback Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silverback Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SBTX) was last updated on 10/8/2025 by MarketBeat.com Staff
